PCI Pharma Services, a global contract development and manufacturing organization (CDMO), has released its first Environmental, Social & Governance (ESG) Report—a detailed overview of its sustainability journey.
Aldena Therapeutics Selects PCI Pharma Services to Manufacture and Distribute Innovative Investigational Treatment for Dermatological Diseases
PCI Pharma Services Announces New Sterile Fill-Finish Capabilities Now Available in Melbourne and San Diego
PCI Pharma Services, a biopharma contract manufacturing partner, has unveiled plans for a $50 million expansion at its Rockford, Illinois, sterile injectables site.
Building on PCI’s leadership in this space with its Philadelphia Biotech Center of Excellence, the new facility is the second expansion building off the success in Philadelphia and will house over 20 dedicated customer suites with multiformat machines for the assembly and packaging of vials, pre-filled syringes, auto-injectors, and pen-cartridge combinations. This machinery can be used for the glucagon-like peptide 1 agonists (GLP-1) class of drugs prescribed to treat diabetes and obesity, as well as those needed for oncology treatment and autoimmune diseases.
PCI Pharma Services (PCI), a global contract development and manufacturing organization (CDMO), opened its Clinical Services Center of Excellence in Bridgewater, MA, the first facility of its kind to support the growing needs of global developers of biologics in the New England region. The new facility will provide increased flexibility and scalability for secondary packaging, distribution and cold chain storage of innovative therapies in development.
PHILADELPHIA--(BUSINESS WIRE)--PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), today announced the opening of its Clinical Services Center of Excellence in Bridgewater, MA, the first facility of its kind to support the growing needs of global developers of biologics in the New England region. The new facility will provide increased flexibility and scalability for secondary packaging, distribution and cold chain storage of innovative therapies in development.
PHILADELPHIA--(BUSINESS WIRE)--PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), today announced a significant expansion of its world-class facility in Tredegar, Wales, UK, designed to help keep pace with the market growth of powerful, targeted oncology therapies.
Thoughtworks, a global technology consultancy that integrates strategy, design and engineering to drive digital innovation, has signed a multi-year agreement with PCI Pharma Services, a global contract development and manufacturing organization (CDMO).
SHORT HILLS, N.J.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ today announced it entered into an agreement with PCI Pharma Services (PCI), a leading integrated global contract development manufacturing organization (CDMO), to provide importation, release and commercialization services in the United Kingdom (UK) for lenzilumab. Under the agreement, PCI will purchase lenzilumab for resale and distribution in the event a Conditional Marketing Authorization is received in the UK for use in patients hospitalized with COVID-19.